The estimated Net Worth of Tom Parmakellis is at least $4.37 mil dollars as of 30 December 2021. Tom Parmakellis owns over 4,500 units of GBS stock worth over $4,371 and over the last 3 years Tom sold GBS stock worth over $0.
Tom has made over 4 trades of the GBS stock since 2021, according to the Form 4 filled with the SEC. Most recently Tom bought 4,500 units of GBS stock worth $6,975 on 30 December 2021.
The largest trade Tom's ever made was buying 4,500 units of GBS stock on 30 December 2021 worth over $6,975. On average, Tom trades about 2,325 units every 48 days since 2021. As of 30 December 2021 Tom still owns at least 9,300 units of GBS stock.
You can see the complete history of Tom Parmakellis stock trades at the bottom of the page.
Tom's mailing address filed with the SEC is 2 ROBERTS STREET, , JANNALI NSW, C3, 2000.
Over the last 4 years, insiders at GBS have traded over $6,891,194 worth of GBS stock and bought 51,106 units worth $85,007 . The most active insiders traders include Science Biosensor Diagnosti..., Spiro Kevin Sakiris y Tom Parmakellis. On average, GBS executives and independent directors trade stock every 12 days with the average trade being worth of $51,467. The most recent stock trade was executed by Spiro Kevin Sakiris on 22 June 2022, trading 5,000 units of GBS stock currently worth $3,250.
GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
GBS executives and other stock owners filed with the SEC include: